Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 9/20 | 0.51 |
| ▸ | LYN | P07948 | 9/20 | 0.51 |
| ▸ | SRC | P12931 | 9/20 | 0.51 |
| ▸ | KDR | P35968 | 9/20 | 0.51 |
| ▸ | HCK | P08631 | 8/20 | 0.51 |
| ▸ | INSR | P06213 | 8/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 8/20 | 0.46 |
| ▸ | RAF1 | P04049 | 4/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13267708 | 0.92 | MAPK14 (0.45) | LCKLYNSRCKDRHCK | |
| SCHEMBL3010702 | 0.91 | INSR (0.57) | LCKLYNSRCKDRHCK | |
| SCHEMBL3004164 | 0.90 | LCK (0.54) | LCKLYNSRCKDRHCK | |
| SCHEMBL3015583 | 0.87 | LCK (0.57) | LCKLYNSRCKDRHCK | |
| SCHEMBL3005151 | 0.85 | LCK (0.67) | LCKLYNSRCKDRHCK | |
| SCHEMBL13267926 | 0.82 | MAPK14 (0.48) | LCKLYNSRCKDRHCK | |
| SCHEMBL3009092 | 0.82 | MAPK14 (0.56) | LCKLYNSRCKDRHCK | |
| SCHEMBL3004106 | 0.81 | BRAF (0.66) | LCKLYNSRCKDRHCK | |
| SCHEMBL3024453 | 0.81 | LYN (0.56) | LCKLYNSRCKDRHCK | |
| SCHEMBL3021329 | 0.81 | LCK (0.67) | LCKLYNSRCKDRHCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184765-A1 | Protein Kinase Inhibitors and Methods for Using Thereof | IRM LLC | 2010-07-22 | — | — | US | claimed |
| EP-2170867-A1 | PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF | IRM LLC (BM) | 2010-04-07 | — | — | EP | claimed |
| WO-2008157131-A1 | PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF | IRM LLC (BM) | 2008-12-24 | — | — | WO | claimed |
| US-20100184765-A1 | Protein Kinase Inhibitors and Methods for Using Thereof | IRM LLC | 2010-07-22 | — | — | US | disclosed |
| EP-2170867-A1 | PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF | IRM LLC (BM) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008157131-A1 | PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF | IRM LLC (BM) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184765-A1 | Protein Kinase Inhibitors and Methods for Using Thereof | BMX, FRK, FYN | LCK 8/4885LYN 5/4885SRC 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.